Influenza vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsEmmanuel Jules HANON, Jean STEPHENNE
Life of this patent
Estimating the term…
Abstract
The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.
Claims22
-46. (canceled)
A method for immunizing a human against influenza virus infection, the method comprising:
- selecting a human who was previously vaccinated with a monovalent first vaccine composition comprising a low amount of an influenza virus antigen or antigenic preparation from an influenza virus of subtype H2, H5, H6, H7 or H9, in combination with an adjuvant, wherein the low antigen amount does not exceed 15 μg of haemagglutinin (HA) per dose, and wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent;
- and
- administering to the selected human a monovalent second vaccine composition comprising a low amount of an influenza virus haemagglutinin (HA) antigen from a variant of the same influenza virus subtype, in combination with an adjuvant, wherein the low HA antigen amount does not exceed 15 μg of HA antigen per dose, wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent;
- and wherein the variant comprises an antigenically distinct HA.
Dependencies are inferred from the claim text.